Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 28 Sep 2023
Price :
$35
*
At a glance
- Drugs Levetiracetam (Primary)
- Indications Mild cognitive impairment
- Focus Registrational; Therapeutic Use
- Acronyms HOPE4MCI
- Sponsors AgeneBio
- 10 Mar 2023 Status changed from active, no longer recruiting to completed.
- 12 Jul 2022 Planned End Date changed from 1 Dec 2022 to 15 Jan 2023.
- 12 Jul 2022 Planned primary completion date changed from 1 Oct 2022 to 5 Dec 2022.